Janus kinase 1 inhibitor <scp>INCB054707</scp> for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase <scp>II</scp> studies*

Abstract

INCB054707 was well tolerated, with responses observed in patients with moderate-to-severe HS. The safety and efficacy findings from these studies demonstrate proof of concept for JAK1 inhibition in HS. The studies are registered on ClinicalTrials.gov (NCT03569371 and NCT03607487).